Dr. David I. Quinn, MD

Dr. Quinn practices at USC Norris Cancer Hospital in Los Angeles, California.

Dr. Quinn's NPI, 1043249584, was assigned on June 30, 2006. Dr. Quinn graduated from University of New South Wales Faculty of Medicine in 1987. Dr. Quinn's California license number on file is A86796.

Dr. Quinn's primary practice is USC Norris Cancer Hospital, at 1441 Eastlake Ave, Los Angeles, CA.

Dr. Quinn's primary practice is USC Norris Cancer Hospital in Los Angeles, California. Dr. Quinn is also affiliated with Keck Hospital of USC. The medical group on file is USC Care Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Quinn practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Quinn's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Quinn is board certified in therapeutic medical physics by the American Board of Radiology. Dr. Quinn has a license on file in California.

Dmand AI lists colorectal cancer and prostate cancer among the conditions Dr. Quinn treats.

CMS data shows 65 Medicare services from Dr. Quinn across 2 procedure codes in 2024, all of them office visits, for 47 Medicare patients. Medicare paid $4,336 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 47 Medicare patients who saw Dr. Quinn in 2024. The largest group is 65 to 74, with 25 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Quinn's median patient age at 75, with 13% women.

In 2022, Dr. Quinn wrote 12 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $173,982 in total drug cost. In 2021, CMS named 17 claims across 1 drug.

Dr. Quinn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Quinn as offering telehealth.

Dmand AI links 9 papers to Dr. Quinn, published from 2015 to 2021. 2018 was the busiest year, with 2. Dr. Quinn's most frequent co-authors are Bruce S. Alpert, MD, Soroush Bazargani, MD and Maurizio Buscarini, MD.

Dmand AI links Dr. Quinn to 28 clinical trials, 14 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Prostatic Neoplasms and Kidney Neoplasms. University of Southern California sponsors the most, 8. Open Payments lists research payments to Dr. Quinn that name 2 trials.

CMS Open Payments shows 463 general payments to Dr. Quinn from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Merck Sharp & Dohme Corporation paid the most, $86,924. It also lists 16 research payments totaling $13,827 from 2016 to 2020, naming 2 clinical trials.

Dmand AI lists 3 awards for Dr. Quinn.

Dr. Quinn graduated from University of New South Wales Faculty of Medicine in 1987. Dr. Quinn is a member of AACR, ACP, ASCO, Australasian College of Physicians and ESMO.

Dr. Quinn is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.